GlassScriptPhysician profile
Rubina Shakil
NPI 1891995841
$3,104.32
in general payments reported to CMS, 2019-2025
27 companies · $473 in 2025
The $473 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $294 · 2021: $483 · 2022: $311 · 2023: $611 · 2024: $557 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,641.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $738.08 | 2021-2025 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $373.58 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $244.12 | 2019-2024 | Spravato |
| Adlon Therapeutics L.P. | $220.62 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $207.54 | 2022-2025 | Rexulti |
| Corium, LLC | $203.08 | 2023-2025 | Azstarys |
| Axsome Therapeutics, INC. | $174.25 | 2023-2025 | Auvelity |
| Avanir Pharmaceuticals, INC. | $148.64 | 2019-2021 | |
| Shire North American Group INC | $92.96 | 2019 | |
| Supernus Pharmaceuticals, INC. | $88.71 | 2022-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $56.93 | 2019-2023 | Jornay Pm |
| Alkermes, INC. | $56.24 | 2022-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $49.28 | 2022-2025 | Rexulti |
| Allergan, INC. | $45.73 | 2019 | |
| Neos Therapeutics, LP | $45.25 | 2024 | Adzenys Xr-Odt |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $41.91 | 2019 | |
| Neuronetics, INC. | $40.64 | 2023 | Neurostar Tms Therapy System |
| Brainsway USA INC | $40.10 | 2023 | |
| Sunovion Pharmaceuticals INC. | $38.03 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $37.90 | 2025 | Relexxii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.59 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $25.40 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $21.13 | 2025 | |
| Idorsia Pharmaceuticals US INC | $20.36 | 2023 | Quviviq |
| Bausch Health US, LLC | $19.07 | 2019 | |
| Sage Therapeutics, LLC | $18.93 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $18.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rubina Shakil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.